NEWSROOM

NO MORE ROUTINE FINGER STICKS⁽¹⁾ FOR AMERICANS WITH DIABETES: ABBOTT'S FREESTYLE^® LIBRE APPROVED IN THE U.S.

Published on: 09.27.2017
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle^® Libre Flash Glucose Monitoring System as a replacement¹ for blood glucose monitoring (BGM) for adults with diabetes in the U.S.

FREESTYLE^® LIBRE FLASH GLUCOSE MONITORING TECHNOLOGY GAINS REIMBURSEMENT APPROVAL FROM THE UNITED KINGDOM'S NATIONAL HEALTH SERVICE

Published on: 09.13.2017
Abbott (NYSE: ABT) today announced that the FreeStyle^® Libre system is now available for reimbursement in the United Kingdom (UK). The National Health Service (NHS) Business Services Authority has approved the listing on the Drug Tariff for the FreeStyle Libre system for people with diabetes using insulin.

REVOLUTIONARY GLUCOSE MONITORING TECHNOLOGY FREESTYLE^® LIBRE NOW REIMBURSED ACROSS JAPAN

Published on: 08.31.2017
Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan has granted national reimbursement for the FreeStyle^® Libre glucose monitoring system effective September 1, 2017.

ABBOTT AND BIGFOOT BIOMEDICAL ANNOUNCE COLLABORATION TO DEVELOP BREAKTHROUGH DIABETES TECHNOLOGIES

Published on: 07.13.2017
Abbott (NYSE: ABT) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle^® Libre glucose sensing technologyⁱ with Bigfoot's insulin delivery solutions in the United States.

ABBOTT SECURES HEALTH CANADA LICENSE FOR FREESTYLE^® LIBRE SYSTEM FOR PEOPLE WITH DIABETES

Published on: 06.29.2017
Abbott (NYSE: ABT) today announced the Health Canada license of its FreeStyle^® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for Canadian adults with diabetes.

ABBOTT ANNOUNCES NATIONAL REIMBURSEMENT FOR FREESTYLE^® LIBRE IN FRANCE, PROVIDING ACCESS TO REVOLUTIONARY TECHNOLOGY FOR PEOPLE WITH DIABETES

Published on: 05.08.2017
Abbott today announced that the French Health Ministry has granted national reimbursement across France for FreeStyle^® Libre—Abbott's revolutionary glucose monitoring technology that removes the need for routine finger sticks1 for people with diabetes.

REAL-WORLD DATA FROM ABBOTT'S FREESTYLE^® LIBRE SHOW ASSOCIATION BETWEEN HIGHER FREQUENCY OF GLUCOSE MONITORING AND IMPROVED GLUCOSE CONTROL FOR PEOPLE WITH DIABETES

Published on: 02.15. 2017
Abbott (NYSE: ABT) today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle^® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels.

ABBOTT RECEIVES FDA APPROVAL FOR THE FREESTYLE LIBRE PROTM SYSTEM, A REVOLUTIONARY DIABETES SENSING TECHNOLOGY FOR HEALTHCARE PROFESSIONALS TO USE WITH THEIR PATIENTS

Published on: 09.28. 2016
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to use with their patients with diabetes.

ABBOTT RECEIVES APPROVAL IN AUSTRALIA FOR FREESTYLE LIBRE - THE REVOLUTIONARY GLUCOSE MONITORING SYSTEM FOR PEOPLE WITH DIABETES

Published on: 02.16.2016
Today, Abbott (NYSE:ABT) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology.

CHILDREN IN EUROPE NOW HAVE ACCESS TO FIRST-OF-ITS-KIND DIABETES SENSING TECHNOLOGY – ELIMINATES ROUTINE FINGER PRICKS

Published on: 02.04. 2016
Today, Abbott (NYSE: ABT) announced that it has obtained CE Mark (Conformité Européenne) for the FreeStyle Libre flash glucose monitoring system indicated for children and teens with diabetes aged 4-17 years old.